When to consider targeted therapies in thrombotic microangiopathies in the modern era: walking the tightrope between cost, safety, and efficacy
Crossref DOI link: https://doi.org/10.1007/s11239-020-02094-8
Published Online: 2020-03-26
Published Print: 2020-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Murphree, Catherine R.
Olson, Sven R.
DeLoughery, Thomas G.
Shatzel, Joseph J.
Text and Data Mining valid from 2020-03-26
Version of Record valid from 2020-03-26
Article History
First Online: 26 March 2020